Literature DB >> 2120286

The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.

D B Hornick1, R B Fick.   

Abstract

It has been shown that pulmonary macrophage (PM) phagocytosis of Pseudomonas aeruginosa (PA) is inhibited in the presence of serum from cystic fibrosis (CF) patients colonized by Pseudomonas, and that these sera contain high concentrations of IgG2 antibodies. The goal of these studies was to investigate the role that IgG2-containing immune complexes (IC) play in this inhibition of both PM and neutrophil phagocytosis. We found that serum IgG2 concentrations were elevated significantly in CF patients with chronic PA colonization and that in selected sera from CF patients with chronic PA colonization (CF + IC, n = 10), the mean IC level was significantly elevated (2.90 +/- 0.22 mg/dl [SEM]). IgG2 comprised 74.5% of IgG precipitated in IC from CF + IC sera. An invitro phagocytic assay of [14C]PA uptake using CF + IC whole-sera opsonins confirmed that endocytosis by normal PM and neutrophils was significantly depressed. Removal of IC from CF + IC sera resulted in significantly decreased serum IgG2 concentrations without a significant change in the other subclass concentrations, and enhanced [14C]PA uptake by PM (26.6% uptake increased to 47.3%) and neutrophils (16.9% increased to 52.6%). Return of the soluble IgG2 IC to the original CF sera supernatants and the positive control sera resulted in return of the inhibitory capacity of the CF + IC sera. We conclude that immune sera from patients with chronic Pseudomonas infections characterized by elevated IgG2 subclass level functions poorly as an opsonin. In these individuals, IgG2 contributes significantly to circulating IC and removal of IC, matched by a simultaneous fall in IgG2, improves bacterial uptake by neutrophil and mononuclear phagocytes. IgG2 antibodies exert antiphagocytic effects by both direct inhibition and the formation of IC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120286      PMCID: PMC296860          DOI: 10.1172/JCI114836

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Inflammatory reaction and airway damage in cystic fibrosis.

Authors:  A D Barton; K Ryder; R V Lourenço; W Dralle; S G Weiss
Journal:  J Lab Clin Med       Date:  1976-09

2.  Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  R B Fick; J Olchowski; S U Squier; W W Merrill; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1986-03

Review 3.  Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.

Authors:  D P Speert
Journal:  Surv Synth Pathol Res       Date:  1985

4.  Circulating immune complexes in patients with cystic fibrosis in relation to clinical features.

Authors:  M E Hodson; I Beldon; J C Batten
Journal:  Clin Allergy       Date:  1985-07

5.  Circulating immune complexes in Lyme arthritis. Detection by the 125I-C1q binding, C1q solid phase, and Raji cell assays.

Authors:  J A Hardin; L C Walker; A C Steere; T C Trumble; K S Tung; R C Williams; S Ruddy; S E Malawista
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

6.  Selective inhibition of phagocytic activity of rabbit alveolar macrophages by cystic fibrosis serum.

Authors:  B Boxerbaum; A Kagumba; L W Matthews
Journal:  Am Rev Respir Dis       Date:  1973-10

7.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Human neutrophils and eosinophils have structurally distinct Fc gamma receptors.

Authors:  A Kulczycki
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

9.  Neutrophil granulocyte function in patients with pulmonary infection.

Authors:  H R Hill; W J Warwick; J Dettloff; P G Quie
Journal:  J Pediatr       Date:  1974-01       Impact factor: 4.406

10.  Circulating immune complexes in cystic fibrosis.

Authors:  M Berdischewsky; M Pollack; L S Young; D Chia; A B Osher; E V Barnett
Journal:  Pediatr Res       Date:  1980-06       Impact factor: 3.756

View more
  6 in total

1.  Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function.

Authors:  J E Salmon; J C Edberg; N L Brogle; R P Kimberly
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

2.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

3.  Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis.

Authors:  B E Britigan; M B Hayek; B N Doebbeling; R B Fick
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

4.  Enhancement of lipopolysaccharide-induced tumor necrosis factor secretion by hyperimmune serum from chronic infected patients.

Authors:  G Kronborg; A Fomsgaard; N Høiby
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

5.  Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.

Authors:  Timothy J Wells; Deborah Whitters; Yanina R Sevastsyanovich; Jennifer N Heath; John Pravin; Margaret Goodall; Douglas F Browning; Matthew K O'Shea; Amy Cranston; Anthony De Soyza; Adam F Cunningham; Calman A MacLennan; Ian R Henderson; Robert A Stockley
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

6.  Expression profiling of genes regulated by Fra-1/AP-1 transcription factor during bleomycin-induced pulmonary fibrosis.

Authors:  Subbiah Rajasekaran; Narsa M Reddy; Wei Zhang; Sekhar P Reddy
Journal:  BMC Genomics       Date:  2013-06-07       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.